ACAN-Botulinum Antitoxin Heptavalent

OPPORTUNITY SUMMARY: ACAN-Botulinum Antitoxin Heptavalent

PURPOSE & SCOPE:

• Procurement Description: The opportunity is for the manufacture and storage of Botulinum Antitoxin (BAT) Bulk Drug Substance as well as BAT in finished dosage form.
• Project Scope and Objectives: The objective is to secure a reliable source of both bulk and finished BAT to meet public health requirements.
• Contract Type and Estimated Value: Specific contract type and estimated value have not been provided in the opportunity details.

BUYER INFORMATION:

• Issuing Organization: Department of Public Works and Government Services (PSPC)
• Contact Details: Kim-Andre Duplin-Vu (SPAC/PSPC) - Email: [email protected]
• Important Dates:
  • Posted Date: December 11, 2025
  • Due Date: January 13, 2026
  • Performance Period: Not specified

MANDATORY REQUIREMENTS:

• Required Certifications/Registrations: Information on specific certifications or registrations required has not been provided.
• Mandatory Qualifications: Not specified in the available data.
• Set-aside Requirements: No information available regarding small business or veteran-owned set-asides.
• Geographic Restrictions: No geographic restrictions mentioned.

TECHNICAL REQUIREMENTS:

• Key Technical Capabilities Needed: Companies must possess capabilities in the manufacture and storage of pharmaceutical products, specifically botulinum antitoxins.
• Specific Technologies/Methodologies: Not explicitly mentioned; expectations may require adherence to pharmaceutical manufacturing and safety regulations.
• Deliverables and Performance Standards: Specific deliverables and performance standards have not been detailed.
• Evaluation Criteria: No specific evaluation criteria provided.

PREFERRED QUALIFICATIONS:

• Nice-to-have Certifications or Experience: No additional certifications or experience requirements specified.
• Preferred Qualifications: No specific qualifications mentioned beyond necessary capabilities for the manufacture of BAT.
• Competitive Advantage Factors: None listed in the documentation.

KEY EVALUATION FACTORS:

• Proposal Evaluation: Details on how proposals will be evaluated are not included.
• Weighting of Criteria: Not mentioned.
• Past Performance Requirements: No information regarding past performance requirements.

This structured summary provides an overview of the ACAN-Botulinum Antitoxin Heptavalent opportunity. Companies interested in this opportunity should focus on developing capabilities for the manufacture and storage of pharmaceutical products, particularly in line with public health requirements.